Business
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab Testing Exec Barry CraigAXIM develops and files for a patent for Novel Tear Collector System SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced two key milestones in preparation of the launch of its DED diagnostics testing initiative. AXIM has signed a supply agreement with Barcelona-based IUL SA (“IUL”) for its iPeak DED readers which will be deployed for diagnostic testing with a focus on lactoferrin levels. This state-of-the-art portable reader is a colorimetric lateral flow reader designed to hold different cassette sizes and can read cassettes of up to five strips and seven lines per strip at a time. iPeak is equipped with “Flash Eye” technology based on the principles of machine vision illumination. Its camera captures the image of the test illuminated from LED lights situated in the most studied geometry to achieve a precise and uniform illumination and enhance the colors of any lateral flow test. The iPeak technology also allows for more sensitivity, which is the main success of its application. AXIM evaluated the iPeak readers in the lab against six other comparable products before deciding on IUL’s state-of-the-art products. The new readers will be calibrated with the new test strips and distributed to the Company’s Medical Advisory Board (MAB) of renowned DED experts for non-clinical field testing on their patients, which includes studying the accuracy and ease of use. These tests are expected to run for a few weeks and the MAB will provide management with data and feedback regarding the test results and any other research findings. The Company’s diagnostic testing process for DED, and specifically for lactoferrin levels as a primary indicator, will include the use of reagent strip samples. These strips will have the patients’ tear sample obtained and applied and then an ophthalmologist or optometrist will run the strips through an iPeak reader to determine lactof...